The company’s orthopedic sales grew in the low single digits for 1Q24, but CONMED faced outsized comparisons and lingering supply issues.

The company grew in the mid-single-digits for 1Q24 but was aided by an unusually robust joint replacement market and one-time revenue items.

According to our estimates, just under 50 companies accounted for more than 85% of all orthopedic revenue in 2023.

Funds will support commercial expansion and clinical activities for the Bridge-Enhanced ACL Restoration (BEAR) Implant.

Funding announcements came from familiar names and supported well-backed markets like spine and enabling technology.

Proceeds will accelerate aprevo personalized lumbar and cervical patient-specific interbody fusion devices.

While Orthofix’s trauma business is growing slower than the market, it has an enormous opportunity in the U.S.

Stay up to date on the orthopedic market’s 4Q performance in 2023 as we update this post with company sales data and industry developments.

The company grew in the low double-digits in 2023 but a strategic review revealed Anika’s need to focus on the greatest growth opportunities.

The company grew in the mid-teens in 2023 with significant growth across product segments and most regions.